29 RESULTS
Go to another page:
COMMENT The CMS correctly analyzed the problem, and they made the right decision. From page 17 of the CMS document, this statement is irrefutable: “Our conclusion is that Biogen’s secondary analysis cannot overturn, definitively confirm, or substitute for, the RC
COMMENT At the level of dementia care, the accelerated approval of aducanumab, and its enabling of the approval of perhaps three other anti-Aβ antibodies (donanemab, lecanemab, gantenerumab) under the same pathway, promises to have a large impact in countries whe
COMMENT This study used a straightforward trial design with a clear outcome, which met the prespecified outcomes. The rate of amyloid-related imaging abnormalities was not trivial but the consequences were manageable. The effect size of reduction of decline was s
COMMENT This study involved persons with dominantly inherited Alzheimer disease mutations who donated plasma samples. The key finding was that ptau181 levels were elevated in both symptomatic and asymptomatic individuals and, in particular, modeling indicated tha
COMMENT Chesebro et al.’s analysis of the relationship between nocturnal blood pressure, white-matter hyperintensities, and cognition demonstrated the expected associations between “reverse dipping” of nocturnal blood pressure and white-matter hyperintensities. T
COMMENT As a co-author on the study from the ARIC cohort by Walker et al., I was impressed when I first saw the data, how important midlife hypertension was, particularly in relation to hypertension appearing first in late life, and of course in relation to normo
COMMENT This set of three cases is interesting and raises concerns for people who had dural transplants before the practice ended. That said, these cases do not prove causality, and the authors acknowledge alternative hypotheses. One might have proposed it was th
COMMENT This fully powered, 18-month study of nilvadipine (NILVAD) by Brian Lawlor and colleagues in persons with clinically diagnosed AD dementia failed to show any cognitive or functional benefits of NILVAD. The trial was well-designed and the published report
COMMENT This study represents the 36-month follow-up of a group of individuals in the AD spectrum who initially underwent Amyvid imaging as part of an Avid Pharmaceuticals-sponsored trial. As was expected from many studies using 11C PiB, the authors found that co
COMMENT I am excited that an amyloid imaging agent will now be available because there are instances where my patients, their families, and I would appreciate the specific information about Alzheimer's disease that it would provide. My hope is that ordering
COMMENT Power et al. have conducted a systematic review of studies of the associations of hypertension and incident Alzheimer's disease. Their bottom line is that their analysis does not offer either convincing support or refutation of the association. I app
COMMENT Schneider et al. present a reanalysis of three studies of memantine in mild to moderate Alzheimer’s disease (AD) in which they were able to isolate the data for the mild subjects. They find no benefits for memantine in milder AD dementia patients. Schneid
COMMENT This adverse effect of cholinesterase inhibitors is well known, but to the extent that it is uncommon, it may be underappreciated. Cholinesterase inhibitors would be expected to cause decreased conduction through the sinoatrial node and to suppress the si
COMMENT A group of researchers at the Arizona Alzheimer’s Consortium led by Richard Caselli and Eric Reiman have been recruiting and following a large number of middle-aged persons who are either heterozygous or homozygous for the ApoE ε4 allele. Their current fi
Go to another page:
